Skip to search formSkip to main contentSkip to account menu

Marqibo

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
Vincristine sulfate liposome injection (VSLI; Marqibo®) is an encapsulated preparation of standard vincristine in sphingomyelin… 
2015
2015
Background: Marqibo® (vincristine sulfate LIPOSOME injection, VSLI) is currently approved in the US for treatment of adults with… 
2013
2013
Vincristine sulfate liposome injection (VSLI; Marqibo®; M) is active in relapsed and refractory lymphomas, and approved in the… 
2012
2012
The FDA has approved vincristine sulfate liposome injection (Marqibo) to treat adults with Philadelphia chromosome–negative acute… 
2011
2011
Marqibo (vincristine sulfate liposome injection, VSLI) is a novel liposomal formulation of vincristine sulfate (VCR) being… 
2010
2010
6507 Background: Management of adult ALL patients who relapse is challenging due to highly drug resistant disease and frequent… 
Highly Cited
2009
Highly Cited
2009
Marqibo, a sphingosomal/cholesterol encapsulation of vincristine sulfate has targeted, increased, and sustained delivery of… 
2009
2009
9067 Background: Preclinical and clinical studies showed that liposomal encapsulation of vincristine sulfate (VCR) results in… 
2007
2007
Background: Vincristine sulfate (VCR) is a cell-cycle specific, lipophilic, anti-cancer drug that inhibits cell division by…